Drug Analysis Zurich Near Me

4worldlovers:
GENFIT is a biopharmaceutical group conducting late stage clinical trials dedicated to improving the lives of patients with liver diseases with high unmet medical needs, with a special focus on rare, severe and acute pathologies.


We concentrate our R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments.

Our translational disease driven approach is the strength of our R&D. We believe in a full comprehension of a disease to discover therapeutic and diagnostic new solutions.

4worldlovers:
The work we do is guided by people living with rare and devastating diseases. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives.

4worldlovers:
ADCs are powerful biopharmaceuticals, delivering highly toxic drugs, or payloads, specifically to cancer cells.


ADCs consist of payloads connected to antibodies through a specific linker. The molecular design enables the highly selective delivery of any payload, often a potent anti-cancer drug, to the diseased tissue, while healthy parts of the human body are spared.


Poor stability and high heterogeneity: Poor connection of the drug to the antibody can lead to ADC instability, allowing the drug to break apart from the antibody prior to reaching the cancerous cells. It also creates ADCs with a wide range of payloads randomly attached, or a heterogeneous ADC pool, that cannot consistently deliver the same amount of drug. Poor ADC stability ultimately increases risk of unwanted side-effects and reduces efficacy.


Limited linker solubility: Payloads are often hydrophobic and thus tend to induce ADC aggregation, or clumping together, in water-based solutions like blood. When ADCs clump together, they cannot bind to cancerous cells efficiently and have reduced efficacy.


Expensive and time intensive development: Current ADC technologies involve complex engineering efforts and multi-step conjugation procedures that take up significant time and require substantial resources.

We are pioneering a proprietary peptide linker technology that will give us the ability to design and develop homogenous, stable, highly soluble and high-quality ADC products in a cost- and time-effective manner.

Superior Design: Our linker technology enables site-specific payload attachment to a privileged attachment site on a specific amino acid (Q295) within the IgG-Fc framework. When a payload is attached to this site, the antibody still maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong peptide bond resulting in exceptional stability in the blood stream and therefore, avoidance of healthy tissue damage. However, once entering a cancer cell via antibody mediated internalization, the linker can be easily broken to release the payload and kill the cancer cell. All three of these properties are key factors to enable the most efficient payload delivery and maximum ADC efficacy.

High linker solubility: Our linkers are hydrophilic, rendering them soluble in water-based solutions like blood. Improved solubility leads to decreased clumping, allowing the ADC to properly bind to cancerous cells without the need to further edit the antibody/payload structures.

Simple manufacturing: We can generate ADCs in one step using “off-the-shelf” antibodies that are native or engineered. The process is fast, cost-efficient and can be easily upscaled without the need for custom antibody synthesis.

Araris’ ADC technology allows for tailor-made manufacturing of safe and highly potent ADC candidates with an improved therapeutic index and the potential to make a clinically meaningful difference for patients with cancer.

As the inventor of the Araris Linker Technology, Philipp has a profound background in Bioconjugation and ADCs. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology.

Isabella holds a Master’s Degree in Molecular Biology from University of Basel and obtained a PhD in Tumorimmunology from University of Zurich (UZH). Before joining Araris, she served as Director Pharmacology at Covagen, a Swiss Biotech that was acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical companies of Johnson & Johnson. She was in charge of the pharmacological characterization of various FynomAbs during pre-clinical development that entered clinical testing.

Bernd received his Master’s Degree from University of Surrey, Guildford, UK in applied toxicology and his PhD in Immunology from University of Würzburg (Germany). Prior to joining Araris, Bernd worked as Vice President Oncology Research at Molecular Partners AG. Before that he worked at Janssen/Covagen AG, Merck Serono as well as at Micromet. In these positions he was responsible for the Discovery, Pharmacology, Toxicology and DMPK activities in close collaboration with CMC, Clinical Development as well as Regulatory Affairs ensuring smooth and successful project transitions from research into early and late-stage clinical development. Bernd has in-depth experience in targeted cancer therapy and the development of novel immuno-oncology modalities (e.g. blinatumomab).